Who
Darren S. Cline
Director
Company insider
Files Form 4 as: Director, Pliant Therapeutics; Director, Pyxis Oncology; Chief Commercial Officer, Xenon Pharmaceuticals; Director, Impel Pharmaceuticals; U.S. Chief Commercial Officer, Gw Pharmaceuticals; Director, Stemline Therapeutics; EVP, Commercial, Seattle Genetics Inc /wa.
In numbers
- Trades disclosed
- 117
- Buys
- 1
- Sells
- 18
- Bought
- $94K
- Sold
- $5.5M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 13 Mar 2015
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2025filed 24 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,800 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K36,979 at $0.98 | filing |
| 13 Jun 2024filed 17 Jun 2024 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,764 at $0.00 | filing |
| 26 Mar 2024filed 28 Mar 2024 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —35,219 at $0.00 | filing |
| 16 Jun 2023filed 20 Jun 2023 | Impel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —13,222 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 12 Apr 2023filed 14 Apr 2023 | Impel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,013 at $0.00 | filing |
| 24 Mar 2023filed 28 Mar 2023 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —139,355 at $0.00 | filing |
| 6 Mar 2023filed 8 Mar 2023 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 31 Mar 2022filed 4 Apr 2022 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —66,831 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Bought | $94K10,000 at $9.39 | filing |
News
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)PYXS · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Darren S. Cline; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.